The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,028.00
Bid: 12,012.00
Ask: 12,016.00
Change: -268.00 (-2.18%)
Spread: 4.00 (0.033%)
Open: 12,226.00
High: 12,266.00
Low: 11,988.00
Prev. Close: 12,296.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sterling eases off recent highs as investors temper vaccine optimism

Thu, 28th Jan 2021 09:22

* Graphic: World FX rates in 2020 http://tmsnrt.rs/2egbfVh

* Graphic: Trade-weighted sterling since Brexit vote http://tmsnrt.rs/2hwV9Hv

LONDON, Jan 28 (Reuters) - The British pound retreated on
Thursday from the multi-month highs it hit in the previous
session, as investors tempered some of their optimism about
COVID-19 vaccinations in the UK.

Sterling surged to its highest since May 2018 against the
dollar in early London trading on Wednesday and later hit an
eight-month high against the euro - a move analysts attributed
to the UK's vaccine rollout being faster than that of Europe.

But the British currency gradually eased off these highs,
falling overnight and opening lower on Thursday.

At 0850 GMT, it was down 0.4% against a stronger dollar, at
$1.3638, compared to its Wednesday high of $1.3759.

Versus the euro, it was down around 0.3% at 88.67 pence per
euro, having peaked at 88.135 in the previous session
.

"We consider Sterling optimism to be excessive and we see
the risk of disappointed expectations. We therefore urge caution
about betting on further Sterling gains," wrote Commerzbank FX
strategist You-Na Park-Heger in a note to clients.

"The markets are clearly ignoring that the current infection
situation in the UK is still very tense," she said.

"There is a high degree of uncertainty as it is difficult to
say how the pandemic is going to develop short-term and when and
how quickly the restrictions can be eased," she added.

Britain has the world's fifth highest death toll from
COVID-19 and Prime Minister Boris Johnson has indicated that the
strict COVID-19 lockdown in England will last until March 8.

The pound has strengthened since a last-minute Brexit deal
was reached in December 2020. But Commerzbank's Park-Heger said
that the impact of Brexit on the UK's economy is still unknown.

The possibility of the Bank of England cutting rates
presents another downside risk for the pound, she said.

Britain said on Thursday that it must receive all of the
COVID-19 vaccines it had ordered and paid for, after some
European Union politicians asked drugmaker AstraZeneca to divert
doses from the UK to make up for a shortfall in supplies.

AstraZeneca was the top drag to the FTSE 100 index
for the second consecutive day.

But some analysts took a positive tone: "The political
jitters between the EU, AstraZeneca and the UK don’t appear to
have a negative impact on GBP. We look for further EUR/GBP
decline over the course of the year as the UK vaccination
advantage (and its likely earlier recovery) and GBP
undervaluation vs EUR are to benefit sterling," wrote ING
analysts in a note to clients.
(Reporting by Elizabeth Howcroft, Editing by William Maclean)

More News
Today 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more
21 May 2024 17:04

LONDON MARKET CLOSE: London dips as eyes turn to UK inflation reading

(Alliance News) - Stock prices in London closed in the red on Tuesday, as investors nervously eye a key UK inflation reading, which could prompt the Bank of England to consider interest rate cuts.

Read more
21 May 2024 15:00

London close: Stocks fall ahead of key inflation reading

(Sharecast News) - London stocks ended in negative territory on Tuesday, influenced by the latest UK economic outlook from the International Monetary Fund (IMF) and comments from US Federal Reserve officials.

Read more
21 May 2024 12:03

CORRECT: Stocks fall but pound up as IMF ups UK forecast

(Correcting London Stock Exchange index prices.)

Read more
21 May 2024 12:00

LONDON MARKET MIDDAY: Stocks fall but pound up as IMF ups UK forecast

(Alliance News) - Stock prices in Europe were lower heading into Tuesday afternoon, with shares in New York also set for a muted open, as a recent rally for equities takes a pause.

Read more
21 May 2024 11:23

AstraZeneca aims for $80 bln in total revenue by 2030

Sees $80 bln in 2030 revenue by 2030

*

Read more
21 May 2024 09:04

LONDON MARKET OPEN: FTSE 100 declines after Asian stocks fall

(Alliance News) - Stock prices in London opened in the red on Tuesday, with some US interest rate cut optimism cooling after hawkish words from Federal Reserve central bankers.

Read more
21 May 2024 08:18

TOP NEWS: AstraZeneca eyes new era of growth with bold new revenue aim

(Alliance News) - AstraZeneca PLC on Tuesday set out its ambition to achieve USD80 billion in annual revenue by the end of the decade as it signalled a new "era of growth."

Read more
21 May 2024 07:52

LONDON BRIEFING: AstraZeneca plots "new era of growth"; SSP confident

(Alliance News) - London's FTSE 100 is called to open lower on Tuesday, following a mixed close in New York overnight, and tepid trade in Asia.

Read more
21 May 2024 07:34

AstraZeneca lays out plans to hit $80bn in revenues by 2030

(Sharecast News) - AstraZeneca has unveiled medium-term growth targets to nearly double group revenues by the end of the decade as it predicts significant growth from existing oncology, biopharmaceuticals and rare disease portfolios.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.